• Publications
  • Influence
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Structure of the nCoV trimeric spike The World Health Organization has declared the outbreak of a novel coronavirus (2019-nCoV) to be a public health emergency of international concern. The virusExpand
  • 1,392
  • 158
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
Building Better Vaccines Vaccines are one of the most effective tools to protect against infectious diseases. Unfortunately, vaccines for diseases with the highest global health burdens, such as HIV,Expand
  • 429
  • 38
The histopathology of fatal untreated human respiratory syncytial virus infection
The pathology of respiratory syncytial virus (RSV) infection was evaluated 1 day after an outpatient diagnosis of RSV in a child who died in a motor vehicle accident. We then identified 11 childrenExpand
  • 330
  • 27
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
Designer Vaccine Respiratory syncytial virus (RSV) is one of the last remaining childhood diseases without an approved vaccine. Using a structure-based approach, McLellan et al. (p. 592) designedExpand
  • 428
  • 25
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Malaria Sporozoite Vaccine Each year, hundreds of millions of people are infected with Plasmodium falciparum, the mosquito-borne parasite that causes malaria. A preventative vaccine is greatlyExpand
  • 527
  • 23
Primary respiratory syncytial virus infection in mice
A mouse model of respiratory syncytial virus (RSV) infection is described. A high‐titered, large‐volume inoculum results in replication of RSV to a high titer in lungs of BALB/c mice. Mice older thanExpand
  • 326
  • 22
Evaluation of candidate vaccine approaches for MERS-CoV
The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause of severe respiratory disease highlights the need for effective approaches to CoV vaccine development. EffortsExpand
  • 155
  • 20
Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis
Human respiratory syncytial virus (RSV) was first isolated in 1956 from a laboratory chimpanzee with upper respiratory tract disease (for general reviews, see references [21][1], [57][2], [102][3],Expand
  • 382
  • 18
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
A single infusion with broadly neutralizing antibody VRC01 resulted in lowered plasma virus load in HIV-1–infected subjects. Passive aggression for HIV Antibodies that neutralize HIV could add to theExpand
  • 259
  • 18
Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes†
ABSTRACT Respiratory syncytial virus (RSV) invades host cells via a type I fusion (F) glycoprotein that undergoes dramatic structural rearrangements during the fusion process. Neutralizing monoclonalExpand
  • 262
  • 16